PALISADE BIO, INC. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
PALISADE BIO, INC. (PALI) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $0 for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-08.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2016-11-08
- PALISADE BIO, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2016-09-30 was $0.00.
- PALISADE BIO, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2016-06-30 was $0.00.
- PALISADE BIO, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2015-09-30 was $0.00.
- PALISADE BIO, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2015-06-30 was $0.00.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 3 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 6 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 9 month |
|---|---|---|---|
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $0.00 derived: sum of 2 quarters · filed 2016-11-08 | $0.00 10-Q · filed 2016-11-08 |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-11 | $0.00 10-Q · filed 2016-08-11 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $0.00 derived: sum of 2 quarters · filed 2016-11-08 | $0.00 10-Q · filed 2016-11-08 |
| 2015-06-30 | $0.00 10-Q · filed 2016-08-11 | $0.00 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |